Potassium channel subfamily K member 10 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Potassium channel subfamily K member 10 shows late clinical disease relevance led by acute respiratory distress syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P57789. Start with acute respiratory distress syndrome, then reuse UniProt P57789 as the stable protein anchor across project notes and exports.
Start with acute respiratory distress syndrome, then reuse UniProt P57789 as the stable protein anchor across project notes and exports.
Potassium channel subfamily K member 10 shows late clinical disease relevance led by acute respiratory distress syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with acute respiratory distress syndrome because it currently carries late clinical support. Linked drugs include ISOFLURANE, SEVOFLURANE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPotassium channel subfamily K member 10
Review this target as Potassium channel subfamily K member 10, mapped to UniProt P57789. Sequence length is 538 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Potassium channel subfamily K member 10 as ChEMBL target CHEMBL2331041, mapped to UniProt P57789. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Potassium channel subfamily K member 10 is the right protein anchor across sources, using UniProt P57789 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute respiratory distress syndrome is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Potassium channel subfamily K member 10 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P57789 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Potassium channel subfamily K member 10 |
| UniProt Accession | P57789 |
| Component Type | Protein |
| Sequence Length | 538 aa |
Potassium channel subfamily K member 10
Review this target as Potassium channel subfamily K member 10, mapped to UniProt P57789. Sequence length is 538 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Potassium channel subfamily K member 10 shows late clinical disease relevance led by acute respiratory distress syndrome. 5 more disease programs remain visible in the same review block.
Start review with acute respiratory distress syndrome because it currently carries late clinical support. Linked drugs include ISOFLURANE, SEVOFLURANE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4745050 | 5.3 | EC50 | 5000.0 | Preclinical |
| CHEMBL4759521 | 5.26 | EC50 | 5500.0 | Preclinical |
| CHEMBL4795261 | 5.25 | EC50 | 5600.0 | Preclinical |
| CHEMBL4747631 | 5.23 | EC50 | 5900.0 | Preclinical |
| CHEMBL4776102 | 5.17 | EC50 | 6800.0 | Preclinical |
| CHEMBL4780579 | 5.12 | EC50 | 7500.0 | Preclinical |
| CHEMBL723 | 5.12 | IC50 | 7600.0 | Approved |
| CHEMBL1417584 | 5.11 | EC50 | 7700.0 | Preclinical |
| CHEMBL4759642 | 5.11 | EC50 | 7700.0 | Preclinical |
| CHEMBL4784090 | 4.58 | EC50 | 26500.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 16 | 2 | 4.7 |
| single protein format | 3 | 10 | 5.1 |